Federal Register #2026-06956

Tariffs and Onshoring Incentives for Patented Pharmaceuticals and APIs

This Presidential Proclamation from the Executive Office of the President addresses national security concerns related to the importation of patented pharmaceuticals and active pharmaceutical ingredients (APIs): - Government Buyer: - Executive Office of the President - Affected Products and Services: - All patented pharmaceuticals and active pharmaceutical ingredients (APIs) imported into the United States - Generic pharmaceuticals and their ingredients are currently exempt - OEMs and Vendors: - No specific OEMs or vendors are named; all manufacturers of patented pharmaceuticals and APIs are impacted - Key Requirements and Notable Details: - Imposes tariffs up to 100% ad valorem on imported patented pharmaceuticals and APIs - Reduced tariffs for companies with approved onshoring plans or from certain allied countries - Exemption for generic pharmaceuticals and their ingredients - Directs the Secretary of Commerce and Secretary of Health and Human Services to negotiate agreements to onshore production and secure supply chains - Ongoing monitoring, enforcement, and potential for future tariff adjustments - Preferential tariff treatment for companies committing to domestic manufacturing

Description

This Presidential Document issued by the Executive Office of the President addresses the national security threat posed by the importation of pharmaceuticals and pharmaceutical ingredients into the United States. It outlines findings that the current import reliance threatens national security and economy, and announces actions including imposing tariffs on patented pharmaceuticals and pharmaceutical ingredients, encouraging onshoring of production, and negotiating agreements to secure supply chains. The proclamation exempts generic pharmaceuticals from tariffs at this time and establishes a plan for monitoring and enforcement.

View original listing